Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00465725

NCT00465725
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with a solid tumour cancer (not a blood cancer), confirmed by a tissue sample or biopsy.
  • Your doctor believes there are no standard treatments left available for you, and that the trial drug (picoplatin) may be an appropriate option.
  • You are 18 years of age or older.
  • You are reasonably active and able to care for yourself, with only limited or no restrictions on daily activities (confirm with trial site).
  • Your doctor estimates you have a life expectancy of at least 12 weeks.

Who may not be able to join:

  • You have cancer that has spread to the brain and is causing symptoms, or is not being controlled with treatment.
  • You have previously had radiation therapy covering a large portion (30% or more) of your bone marrow.
  • You have a serious ongoing medical condition that could make it unsafe for you to participate in the trial.
  • You have had stomach or bowel surgery that could affect how your body absorbs a tablet or oral medication.
  • You have an active stomach or bowel condition, such as inflammatory bowel disease, gastritis, ulcers, or bleeding in the digestive tract.
  • There is evidence that your pancreas has been damaged or that you have active pancreatic inflammation.
  • You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Poniard Pharmaceuticals
Registry
clinicaltrials_gov
Start date
1 April 2007
Est. completion
1 July 2009

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

MTD; Comparison of platinum levels excreted in urine from 0-8 and 8-24 hours after start of IV or oral drug

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov